Dec 20, 2019

Stem Cells for Equine Uveitis

Posted by Bob under Horse Stem Cell Therapy

VetStem recently attended and exhibited at the annual American Association of Equine Practitioners conference.  The convention brings equine veterinarians and veterinary professionals together from across the United States to what is the world’s largest continuing education event dedicated to equine practice.

VetStem sponsored a presentation by Dr. Roland Thaler, who has been utilizing VetStem Cell Therapy for over ten years.  In his presentation, Dr. Thaler discussed an equine patient, Mac, who was treated with VetStem Cell Therapy for non-responsive uveitis.  Uveitis is characterized by inflammation of the uveal tract of the eye and can be a one-time episode or recurrent.  Recurrent uveitis can lead to permanent damage and even blindness.

Though the cause of recurrent uveitis is unclear, there is evidence to suggest it may be immune-mediated.  Stem cells have demonstrated the ability to reduce inflammation and to modulate the immune system.  Preliminary in-vitro and clinical case series results demonstrate safety and that stem cells may be effective in controlling recurrent uveitis including one where three out of four horses had a favorable response to treatment with stem cells.  

In Mac’s case, his uveitis was non-responsive, meaning his symptoms could not be managed with traditional therapies.  Dr. Thaler recommended treatment with VetStem Cell Therapy.  Mac was treated in July 2019 and the cells were administered via intravenous injection as well as subconjunctival.  Dr. Thaler reported that 14 days after treatment, Mac had marked improvement of comfort and his medications were able to be reduced.

Mac received a second treatment with stem cells in early October 2019.  Despite his initial improvement, Mac’s condition worsened and he was retired from competition due to visual impairment. 

Dr. Thaler noted that Mac tolerated the subconjunctival injections remarkably well.  Mac’s initial response to treatment was promising leading Dr. Thaler to recommend treating recurrent uveitis as early in the disease process as possible.    

Share

Comments are closed.